This is a consensus statement from an international group, mostly of clinical endocrinologists.
MEN1 and MEN2 are hereditary cancer syndromes. The commonest tumors secrete PTH …

In the past few years, the introduction of novel PET tracers labelled with 68 Ga has changed
the diagnostic approach to neuroendocrine tumours (NET) in specialized centres. Although …

Background Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has
shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two …

Purpose Knowledge of clinical course of pancreatic endocrine carcinomas (PECs) is poor.
This study aimed to determine the time to progression of advanced PECs, and to identify …

Gianfranco Delle Fave a Dik J. Kwekkeboom b Erik Van Cutsem c Guido Rindi d Beata Kos-Kudla
e Ulrich Knigge f Hironobu Sasano g Paola Tomassetti h Ramon Salazar i Philippe …

Purpose We evaluated the pattern of chromogranin A (CgA) plasma levels in a large number
of patients with neuroendocrine tumors (NETs), in a series of patients with chronic atrophic …

Purpose Everolimus improved median progression-free survival by 6.4 months in patients
with advanced pancreatic neuroendocrine tumors (NET) compared with placebo in the …

Purpose 18 F-FDG positron emission tomography (PET) value for the assessment of neuro-endocrine
tumours (NET) is limited. Preliminary studies indicate that 18 F-DOPA and 68 Ga-…

Several authors reported the superiority of 68 Ga-DOTANOC PET/CT to conventional
imaging (CI) for the assessment of neuroendocrine tumors (NET). However, the detection of a …

In the present review article we presented the major technical innovations regarding the
diagnosis of NET with PET/CT 68Ga-DOTA-peptides compounds over conventional radiologic …